PRESS RELEASE published on 03/14/2024 at 09:00, 2 years ago Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing Partex NV collaborates with Sanofi in AI-based dossier enrichment for out-licensing, enhancing Sanofi's portfolio with Partex's AI technology. CEO Gunjan Bhardwaj expresses dedication to innovative drug discovery Drug Discovery AI Technology Partex NV Sanofi Out-licensing
PRESS RELEASE published on 03/14/2024 at 09:00, 2 years ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
PRESS RELEASE published on 03/14/2024 at 08:30, 2 years ago Bayer and Aignostics to collaborate on next generation precision oncology Bayer and Aignostics partner to enhance precision oncology through AI-driven target identification and computational pathology algorithms. Collaboration aims to accelerate oncology drug research and development AI Precision Oncology Bayer Aignostics Target Identification
PRESS RELEASE published on 03/14/2024 at 08:27, 2 years ago EQS-WpÜG: Takeover Offer / Target company: ENCAVIS AG; Bidder: Elbe BidCo AG (currently still named Blitz 21-823 AG) Elbe BidCo AG, previously known as Blitz 21-823 AG, announces a takeover offer for Encavis AG. The offer price is EUR 17.50 per share, representing a 33% premium Encavis AG Takeover Offer Investment Agreement Elbe BidCo AG Voluntary Public Takeover
PRESS RELEASE published on 03/14/2024 at 08:06, 2 years ago Hapag-Lloyd AG: Supervisory Board renews appointment of Rolf Habben Jansen and extends contract of Donya-Florence Amer Hapag-Lloyd AG's Supervisory Board renews CEO Rolf Habben Jansen's contract until 2029 and extends CIO/CHRO Donya-Florence Amer's contract until 2030. Board emphasizes strategic continuity and digital transformation Supervisory Board Contract Renewal Hapag-Lloyd AG Rolf Habben Jansen Donya-Florence Amer
REGULATED PRESS RELEASE published on 03/14/2024 at 08:01, 2 years ago Saint-Gobain accélère dans la chimie de la construction et accompagne le développement de technologies de pointe pour la décarbonation Saint-Gobain's Construction Chemistry activity develops new low-carbon additives for cement and concrete, fostering partnerships with Fortera and Ecocem. Initiatives align with 'Grow & Impact' strategic plan Saint-Gobain Croissance Durable Chimie De La Construction Partenariats Ciment Bas Carbone
REGULATED PRESS RELEASE published on 03/14/2024 at 08:01, 2 years ago Saint-Gobain accelerates in construction chemicals and supports the development of breakthrough decarbonization technologies Saint-Gobain Construction Chemicals expands using new low-carbon technologies in cement and concrete production to drive growth and foster partnerships, aligning with its sustainable strategies Saint-Gobain Construction Chemicals Sustainable Growth Low-carbon Technologies Cement Production
PRESS RELEASE published on 03/14/2024 at 08:00, 2 years ago ecotel communication ag: Growth in all segments – B2B business pick-ing up considerably ecotel communication ag reports growth in all segments including significant B2B business expansion. Financial highlights for 2023 showcased positive results and strong forecast for future growth Financial Results Annual Report Growth Forecast Ecotel Communication AG B2B Business
PRESS RELEASE published on 03/14/2024 at 08:00, 2 years ago Deutsche Familienversicherung: Profitability target achieved and new business target exceeded Deutsche Familienversicherung AG exceeds new business target and achieves profitability goal for 2023, reporting robust financial results Financial Results Insurance Industry Profitability Deutsche Familienversicherung AG New Business Target
PRESS RELEASE published on 03/14/2024 at 08:00, 2 years ago Epigenomics AG publishes financial results for fiscal year 2023 Epigenomics AG reports financial results for fiscal year 2023 including key figures and operational developments. The company undergoes restructuring measures and enters into agreements to ensure future sustainability Financial Results Epigenomics AG Fiscal Year 2023 Restructuring Measures Business Outlook
Published on 03/27/2026 at 12:30, 2 hours 13 minutes ago Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 2 hours 43 minutes ago Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 11:00, 3 hours 43 minutes ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 5 hours 13 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 14:31, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 03/27/2026 at 14:29, 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: AEW UK REIT plc
Published on 03/27/2026 at 07:00, 7 hours 43 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 20 hours 26 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 20 hours 26 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 20 hours 43 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026